[go: up one dir, main page]

FR10C0035I2 - Composition immunogene de lh-rh et procedes concernant cette composition - Google Patents

Composition immunogene de lh-rh et procedes concernant cette composition

Info

Publication number
FR10C0035I2
FR10C0035I2 FR10C0035C FR10C0035C FR10C0035I2 FR 10C0035 I2 FR10C0035 I2 FR 10C0035I2 FR 10C0035 C FR10C0035 C FR 10C0035C FR 10C0035 C FR10C0035 C FR 10C0035C FR 10C0035 I2 FR10C0035 I2 FR 10C0035I2
Authority
FR
France
Prior art keywords
same
immunogenic composition
methods concerning
concerning
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR10C0035C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Publication of FR10C0035I1 publication Critical patent/FR10C0035I1/fr
Application granted granted Critical
Publication of FR10C0035I2 publication Critical patent/FR10C0035I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
FR10C0035C 1997-07-09 2010-07-09 Composition immunogene de lh-rh et procedes concernant cette composition Active FR10C0035I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO7768A AUPO776897A0 (en) 1997-07-09 1997-07-09 A method of achieving production gains in livestock and agents useful for same
PCT/AU1998/000532 WO1999002180A1 (fr) 1997-07-09 1998-07-09 Composition immunogene de lh-rh et procedes concernant cette composition

Publications (2)

Publication Number Publication Date
FR10C0035I1 FR10C0035I1 (fr) 2010-08-27
FR10C0035I2 true FR10C0035I2 (fr) 2012-06-22

Family

ID=3802056

Family Applications (2)

Application Number Title Priority Date Filing Date
FR10C0035C Active FR10C0035I2 (fr) 1997-07-09 2010-07-09 Composition immunogene de lh-rh et procedes concernant cette composition
FR10C0040C Active FR10C0040I1 (fr) 1997-07-09 2010-08-24 Composition immunogene de lh-rh et procedes concernant cette composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR10C0040C Active FR10C0040I1 (fr) 1997-07-09 2010-08-24 Composition immunogene de lh-rh et procedes concernant cette composition

Country Status (19)

Country Link
US (6) US7534441B2 (fr)
EP (4) EP2316477A1 (fr)
JP (3) JP5116916B2 (fr)
KR (2) KR20060101554A (fr)
AT (1) ATE458493T1 (fr)
AU (2) AUPO776897A0 (fr)
CA (1) CA2294865C (fr)
CY (2) CY1109968T1 (fr)
DE (2) DE69841521D1 (fr)
DK (1) DK1007084T3 (fr)
ES (1) ES2339308T3 (fr)
FR (2) FR10C0035I2 (fr)
LU (1) LU91711I2 (fr)
NZ (1) NZ502080A (fr)
PL (1) PL200495B1 (fr)
PT (1) PT1007084E (fr)
TW (1) TWI235666B (fr)
WO (1) WO1999002180A1 (fr)
ZA (1) ZA986074B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO776897A0 (en) 1997-07-09 1997-07-31 Csl Limited A method of achieving production gains in livestock and agents useful for same
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
ATE286511T1 (de) 1999-02-17 2005-01-15 Pfizer Prod Inc Fusionsproteine mit trägern welche eine doppelte immunantwort induzieren
US8088734B2 (en) * 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
US20090028886A1 (en) * 2004-08-04 2009-01-29 Cytos Biotechnology Ag Carrier conjugates of gnrh-peptides
BRPI0611390A2 (pt) * 2005-06-01 2010-09-08 Pfizer Prod Inc composições de vacina e uso de composições compreendendo vacina anti-lhrh na preparação de um medicamento para tratar incontinência urinária
WO2008110912A1 (fr) * 2007-03-14 2008-09-18 Pfizer Inc. Régulation de fertilité chez des chevaux
BR112015011897B1 (pt) 2012-12-03 2021-11-03 Pfizer Inc Compostos moduladores seletivos do receptor de andrógeno e seu uso
KR101918381B1 (ko) * 2017-01-11 2018-11-13 이경민 칠보 공예품을 제조하는 방법과 이에 의하여 제조되는 칠보 공예품
KR102477054B1 (ko) * 2020-03-24 2022-12-14 주식회사 바이오앱 웅취 제거용 재조합 단백질 및 이를 포함하는 백신 조성물
AU2024296166A1 (en) * 2023-07-07 2025-09-25 Ouro Fino Saúde Animal Ltda Modified gnrh peptide and its conjugate for mammalian immunocastration, manufacturing method, composition and kit

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963691A (en) * 1974-10-07 1976-06-15 Merck & Co., Inc. Synthetic antigens of luteinizing hormone releasing hormone
DE3411224A1 (de) 1984-03-27 1985-10-10 Hoechst Ag, 6230 Frankfurt Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren
NZ220932A (en) * 1986-07-03 1990-05-28 Victoria State Composition comprising an antigenic substance, such as lhrh, conjugated to at least two different carriers and method of immunological castration and spaying
NZ221306A (en) 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
AU602187B2 (en) * 1987-01-14 1990-10-04 Commonwealth Scientific And Industrial Research Organisation Anti-reproductive hormone
GB2228262B (en) * 1989-01-25 1992-10-07 Nat Inst Immunology Antigenic derivative of gnrh
AU5186090A (en) * 1989-02-23 1990-09-26 Colorado State University Research Foundation Gnrh analogs for destroying gonadotrophs
NL8900726A (nl) 1989-03-23 1990-10-16 Stichting Centr Diergeneeskund Peptide, immunogene samenstelling en vaccin- of geneesmiddelpreparaat; werkwijze voor het immuniseren van een zoogdier tegen lhrh, en werkwijze voor het verbeteren van de vleeskwaliteit van varkens.
US5138034A (en) * 1989-07-12 1992-08-11 The Green Cross Corporation Method of fractionating plasma proteins
CA2040441C (fr) 1989-08-25 1998-03-31 Gregory J. Russell-Jones Proteines de fusion
US5324512A (en) 1990-12-26 1994-06-28 The Population Council [Gln']-luteinizing hormone releasing hormone conjugate of tetanus vaccine and its uses
DK0501882T3 (da) * 1991-03-01 2000-12-11 Merial Sas Fremgangsmåde til anti-LHRH immunoneutralisering af ikke-kastrerede husdyrhanner og peptider dertil
CA2114125A1 (fr) * 1991-07-26 1993-02-18 Wayne G. Reilly Systeme d'administration de vaccins avec ajout automatique d'adjuvant et sa production
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
ZA934199B (en) 1992-06-18 1994-01-10 Akzo Nv Carrier system against gnrh
US5614487A (en) 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
US5885966A (en) * 1995-06-07 1999-03-23 Dlo Instituut Voor Dierhouderij En Diergezondheid Peptide, immunogenic composition and vaccine or medical preparation, a method to immunise animals against the hormone LHRH, and analogs of the LHRH tandem repeat peptide and their use as vaccine
JP3959746B2 (ja) 1995-06-07 2007-08-15 ペプスキャン システムズ ベー．フェー． 改良ペプチド、免疫原性組成物およびワクチンまたは医薬製剤、ｌｈｒｈホルモンに対する動物の免疫方法、ならびにｌｈｒｈ縦列反復ペプチドおよびそのワクチンとしての使用
AU7468196A (en) 1995-10-27 1997-05-15 Merck & Co., Inc. Conjugates of gonadotropin releasing hormone
AUPO776897A0 (en) * 1997-07-09 1997-07-31 Csl Limited A method of achieving production gains in livestock and agents useful for same
US6013770A (en) 1997-07-21 2000-01-11 Washington State University Chimeric contraceptive vaccines

Also Published As

Publication number Publication date
CY2010013I2 (el) 2012-01-25
US8741303B2 (en) 2014-06-03
US7534441B2 (en) 2009-05-19
FR10C0035I1 (fr) 2010-08-27
EP2191839A3 (fr) 2010-09-08
JP2001509489A (ja) 2001-07-24
US20140271695A1 (en) 2014-09-18
EP2191839A2 (fr) 2010-06-02
CY2010013I1 (el) 2012-01-25
AU725562B2 (en) 2000-10-12
US20120328639A1 (en) 2012-12-27
US20090291098A1 (en) 2009-11-26
ATE458493T1 (de) 2010-03-15
US20110293647A1 (en) 2011-12-01
KR20060101554A (ko) 2006-09-25
WO1999002180A1 (fr) 1999-01-21
PT1007084E (pt) 2010-04-08
EP2196213A1 (fr) 2010-06-16
LU91711I2 (fr) 2010-09-28
JP2010059167A (ja) 2010-03-18
AUPO776897A0 (en) 1997-07-31
CY1109968T1 (el) 2012-01-25
NZ502080A (en) 2001-09-28
PL338037A1 (en) 2000-09-25
EP1007084B1 (fr) 2010-02-24
KR100680631B1 (ko) 2007-02-09
CA2294865C (fr) 2013-05-21
US20060024290A1 (en) 2006-02-02
ES2339308T3 (es) 2010-05-18
KR20010021623A (ko) 2001-03-15
EP1007084A1 (fr) 2000-06-14
DE122010000033I1 (de) 2011-12-01
FR10C0040I1 (fr) 2010-10-15
ZA986074B (en) 1999-03-16
DK1007084T3 (da) 2010-05-03
JP2013006862A (ja) 2013-01-10
JP5116916B2 (ja) 2013-01-09
PL200495B1 (pl) 2009-01-30
JP5231378B2 (ja) 2013-07-10
EP1007084A4 (fr) 2003-07-02
TWI235666B (en) 2005-07-11
CA2294865A1 (fr) 1999-01-21
DE69841521D1 (de) 2010-04-08
EP2316477A1 (fr) 2011-05-04
US20090226484A1 (en) 2009-09-10
AU8200198A (en) 1999-02-08

Similar Documents

Publication Publication Date Title
FR10C0035I2 (fr) Composition immunogene de lh-rh et procedes concernant cette composition
EP0568606A4 (fr)
TW200504198A (en) Glyceride compositions and methods of making and using same
ATE402607T1 (de) Delta-4-desaturase-gene und ihre verwendung
EP0431302A3 (en) Use of curable cycloaliphatic derivatives in putty compositions
AU4589901A (en) Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis
TR200200068T2 (tr) Nematisital triflüorobütenler
WO2000076933A3 (fr) Compositions de platre resistantes a l'eau
HUT40331A (en) Process for preparing pharmaceutical compositions containing a combination of dihidro-pyridines and ace-inhibitors
WO2001040177A3 (fr) Esters de vitamine d3 et utilisation de ces ceux-ci
TW200603746A (en) Iron sulfate based phosphate adsorbent
UA29473C2 (uk) Фунгіцидна композиція, спосіб боротьби з фітопатогенними грибами
GB9807114D0 (en) Novel process
TW277050B (fr)
DE69832880D1 (de) Frazzled nukleotidsequenzen, expressionsprodukte, zusammensetzungen und verwendungen
MD780G2 (ro) Compoziţie de rachiu
JO1999B1 (en) Isotopes of the hormone 'LH-RH' have their uses and the chemical compounds they contain
MD557G2 (ro) Compozţie de ingrediente pentru balsam
TNSN03036A1 (en) Stabilized brivudine topical formulations
GR850297B (fr)
ID16012A (id) Proses untuk produksi butir-butir pupuk.
MY131905A (en) Compositions comprising cyclohexamantane
BG103572U (en) Means for fertilizing the soil and neutralizing the soil acidity
IT1267840B1 (it) Bruciatore di gas atmosferico del tipo a miscelazione cosiddetta iperstechiometrica
BG101740A (en) Toothpaste with vegetable extract